Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Manulife Financial Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Manulife Financial Corporation trades at $41.29 (market cap $68.50B). The key difference: Manulife Financial Corporation is the larger of the two by market cap, and Manulife Financial Corporation pays a 3.23% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MFC | |
|---|---|---|
Market Cap | $39.89B | $68.50B |
Sector | Health | Financials |
52-Week High | $491.22 | $41.49 |
52-Week Low | $278.09 | $29.90 |
Enterprise Value | $38.15B | $65.07B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Manulife Financial (MFC) trades at $41.29, down 0.48% with a bullish technical outlook. The stock shows solid fundamentals with revenue growth to $53.01B in 2025 and net income of $5.78B, though Q1 2026 earnings missed expectations. Analyst consensus is strongly bullish with 57% buy ratings, supported by positive AI developments and dividend payments.
MFC presents a compelling investment case with strong profitability metrics (ROE 13.14%) and reasonable valuation (P/E 16.89). Key risks include regulatory scrutiny in Hong Kong and wealth management outflows. The company's AI leadership and Asia growth provide upside potential, though investors should monitor execution on recent strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
